VRTX · Archive

VRTX · Monthly research archive

Every month we publish a fresh rating. Read prior months' commentary, ratings, and price trend at a glance.

2026-05Güçlü Al

VRTX May 2026 · strong-buy

Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.

$429.82